Xeris Biopharma to Report Full Year 2025 Financial Results and Provide Full Year 2026 Guidance on March 2, 2026

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a biopharmaceutical innovator, has announced the release of its fourth quarter and full year 2025 financial results, scheduled for March 2, 2026. The Company will present its findings before the U.S. markets open and provide guidance for the full year 2026. This pivotal earnings call, hosted by management at 8:30 a.m. Eastern Time, will offer insights into the Company’s financial performance and operational milestones, emphasizing its commitment to enhancing patient lives through innovative therapies.

To participate in the conference call, interested parties can pre-register via the provided link, which will generate a confirmation email. Listeners can join the live webcast through Xeris' Investor Relations page or by using an alternative link. Xeris encourages attendees to register at least ten minutes in advance. Following the call, a replay will be accessible on the Company’s Investor Relations site, ensuring that stakeholders have ample opportunity to review the discussions.

Xeris Biopharma has established itself in the pharmaceutical landscape with three marketed products: Recorlev®, addressing endogenous Cushing’s syndrome; Gvoke®, a ready-to-use liquid glucagon for severe hypoglycemia; and Keveyis®, a treatment for primary periodic paralysis. The Company also boasts a robust pipeline, which includes XP-8121, a Phase 3-ready, once-weekly subcutaneous injection for hypothyroidism, along with various early-stage programs supported by their proprietary XeriSol® and XeriJect® technology platforms.

Headquartered in Chicago, IL, Xeris is poised for growth, and the upcoming conference call is an opportunity for investors and analysts to deepen their understanding of the Company’s strategies and future directions. For further details, visit www.xerispharma.com or connect via social media platforms.

As Xeris Biopharma prepares to report its full-year 2025 financial results and provide guidance for 2026, investors should be closely evaluating both the company’s performance and its market outlook. The scheduled conference call on March 2, 2026, is an important event for stakeholders to assess operational and financial metrics, particularly given the company's focus on innovative therapies such as Recorlev, Gvoke, and Keveyis.

Historically, Xeris has demonstrated strong revenue growth due to its differentiated product offerings within the biopharmaceutical space. As the FDA has increasingly cleared biopharmaceuticals for market, Xeris’s ability to leverage its proprietary XeriSol and XeriJect technology platforms could be a key highlight in the earnings call. Investors should keep an eye on the performance of these existing products as well as the status of their clinical pipeline—especially XP-8121, a once-weekly injection for hypothyroidism, which could significantly enhance their portfolio if it succeeds in Phase 3 trials.

Market analysts should note the competitive landscape, particularly in the glucagon and therapeutic sectors. Gvoke's performance in a growing market for diabetes management solutions may serve as a bellwether for future growth trajectories. Additionally, insights into operational efficiencies and potential partnerships during the call could provide further context to Xeris’ strategic direction and help investors gauge whether to increase their positions.

In anticipation of the results, investors should consider current price levels and market sentiment around the biopharmaceutical sector. Positive guidance for 2026 could stimulate bullish sentiment, while conservative expectations may introduce volatility. Engaging with the conference call and closely monitoring the Q&A could shed light on management’s outlook and influence stock performance in the near term. Keeping abreast of developments after the call through Xeris' Investor Relations page will also be crucial for making informed investment decisions.